



**For immediate release**

November 8, 2006

## **Cervical cancer vaccination funding for Australian girls rejected**

CSL Limited, Australia's leading biopharmaceutical company, today announced that at last week's meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) rejected CSL's funding application for its cervical cancer vaccine GARDASIL®.

CSL applied to the PBAC for National Immunisation Program funding for the vaccine for three groups of women, based on the use approved by the Therapeutic Goods Administration (TGA). An ongoing cohort of 11-12 year old girls delivered through a schools-based program at the end of primary school, a catch-up program for high-school girls (aged 13-18) delivered through secondary schools and a general practice based program for women aged 19-26.

Although disappointed, CSL remains committed to securing Government funding for GARDASIL in Australia and will continue to work closely with the Government and PBAC until this is achieved.

**For more information about CSL Limited, visit [www.csl.com.au](http://www.csl.com.au)**

### **Media Contacts**

Australia and New Zealand  
Dr Rachel David  
Director of Public Affairs  
Phone: 0401 775 779

### **Investor Contact:**

Mark Dehring  
Director of Investor Relations  
Phone: 61 3 9389 2818  
Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)